What is HC Wainwright’s Forecast for IONS FY2027 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Ionis Pharmaceuticals in a research note issued on Wednesday, March 25th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.35) per share for the year. HC Wainwright has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share.

IONS has been the subject of a number of other reports. Stifel Nicolaus raised their price target on shares of Ionis Pharmaceuticals from $73.00 to $77.00 and gave the company a “hold” rating in a report on Thursday, February 26th. Morgan Stanley set a $95.00 price objective on shares of Ionis Pharmaceuticals and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wells Fargo & Company upped their price objective on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Thursday, January 22nd. Finally, TD Cowen reissued a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $89.60.

Ionis Pharmaceuticals Trading Up 4.3%

NASDAQ IONS opened at $72.70 on Thursday. The stock has a market cap of $12.01 billion, a P/E ratio of -29.79 and a beta of 0.31. The company’s fifty day simple moving average is $79.05 and its 200-day simple moving average is $75.57. The company has a current ratio of 3.83, a quick ratio of 3.81 and a debt-to-equity ratio of 2.76. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). The company had revenue of $203.33 million during the quarter, compared to analysts’ expectations of $156.07 million. Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.The firm’s revenue was down 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.66) EPS.

Insider Activity at Ionis Pharmaceuticals

In other news, CEO Brett P. Monia sold 126,670 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $75.20, for a total value of $9,525,584.00. Following the completion of the sale, the chief executive officer owned 242,662 shares of the company’s stock, valued at approximately $18,248,182.40. The trade was a 34.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth L. Hougen sold 215,048 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $72.40, for a total transaction of $15,569,475.20. Following the transaction, the executive vice president directly owned 92,832 shares in the company, valued at $6,721,036.80. The trade was a 69.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,035,882 shares of company stock worth $80,492,247 over the last 90 days. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 72.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company’s stock valued at $19,686,000 after acquiring an additional 274,310 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Ionis Pharmaceuticals by 6.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company’s stock worth $19,895,000 after purchasing an additional 39,794 shares during the last quarter. Focus Partners Wealth lifted its stake in Ionis Pharmaceuticals by 30.1% during the first quarter. Focus Partners Wealth now owns 9,832 shares of the company’s stock worth $297,000 after purchasing an additional 2,277 shares during the last quarter. Creative Planning boosted its holdings in Ionis Pharmaceuticals by 47.5% in the second quarter. Creative Planning now owns 53,289 shares of the company’s stock worth $2,105,000 after purchasing an additional 17,167 shares during the period. Finally, Swiss National Bank boosted its holdings in Ionis Pharmaceuticals by 4.8% in the second quarter. Swiss National Bank now owns 288,600 shares of the company’s stock worth $11,403,000 after purchasing an additional 13,300 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $120 and maintained a “buy” rating — implying roughly 65% upside from the recent reference price; this is a strong vote of confidence in Ionis’ pipeline and likely helped lift sentiment. HC Wainwright PT Raise
• Positive Sentiment: Needham & Company increased its price target to $105 and reiterated a “buy” rating — another analyst upgrade that supports higher share-price expectations. Needham PT Raise
• Positive Sentiment: The FDA granted priority review to Ionis’ NDA for zilganersen for Alexander disease, setting a Sept. 22, 2026 decision date — a meaningful regulatory catalyst since priority review accelerates the timeline and reflects the agency’s view of potential benefit. FDA Priority Review for Zilganersen
• Neutral Sentiment: Short-interest reports posted this week show zero shares / zero days-to-cover data and flagged increases as NaN — likely a reporting/data anomaly rather than a meaningful change to short positioning. Investors should watch for corrected data if short activity is a concern.
• Negative Sentiment: EVP Eugene Schneider sold 5,812 shares (filed sale, avg price ~$70.97) — insider selling can be perceived negatively, though the executive still holds a large position. The size and timing may temper enthusiasm for some investors. Insider Sale

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.